Dr. Sara Elizabeth Kehoe, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 37 Main St, Ashland, MA 01721 Phone: 508-881-7700 |
Ms. Reshma Jayant Ghanekar, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 223 America Blvd, Ashland, MA 01721 Phone: 508-371-3147 |
Dr. Stuart R Rosenthal, DMD Dentist Medicare: Medicare Enrolled Practice Location: 30 Main St, Suite 2, Ashland, MA 01721 Phone: 508-881-4266 Fax: 508-881-3983 |
Dr. Sandra Fiona Cove, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 37 Main St, Ashland, MA 01721 Phone: 508-881-7700 Fax: 508-881-7049 |
Dr. Marc F Rubin, DMD Dentist Medicare: Medicare Enrolled Practice Location: 30 Main St, Suite 2, Ashland, MA 01721 Phone: 508-881-4266 Fax: 508-881-3983 |
Rachael Gilardetti Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 37 Main St, Ashland, MA 01721 Phone: 508-881-7700 |
John William Zarrella, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 171 Main Street, Suite 100, Ashland, MA 01721 Phone: 508-881-1280 Fax: 508-881-3529 |
Dr. Selim C Alptekin, D.M.D. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 214 Main St, Ashland, MA 01721 Phone: 508-881-1290 Fax: 508-881-8468 |
Dr. Armond M Enos Jr., D.D.S;M.S.D Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 300 Eliot St, Ashland, MA 01721 Phone: 508-881-4550 Fax: 508-881-2520 |
Jonghee M Hong, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 171 Main St, Suite 102, Ashland, MA 01721 Phone: 508-881-7272 Fax: 508-881-7274 |
Fatima Hussein Ba Haroun, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 12 Rodman Rd, Ashland, MA 01721 Phone: 508-969-6912 |
Dr. Tej Ashok Shah, D.M.D Dentist Medicare: Medicare Enrolled Practice Location: 5 Homer Ave, Ashland, MA 01721 Phone: 508-387-3733 |
News Archive
PDL BioPharma, Inc. (PDL) today announced that it will pay a $200 million special dividend to stockholders, with part of the proceeds from the $300 million securitization transaction completed on November 2, 2009.
Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).
Scientists at the Mayo Clinic in Rochester, Minn., studied a group of 17 healthy volunteers between the ages 18 and 40 for a week in their homes, monitoring how much each of the typically slept and ate.
CAR T-cell immunotherapies are advanced therapy medicinal products manufactured from human primary living cells procured by hospitals or blood banks.
› Verified 3 days ago